EDIT
Price
$1.92
Change
+$0.11 (+6.11%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
159.89M
54 days until earnings call
IGXT
Price
$0.17
Change
-$0.00 (-0.00%)
Updated
May 16 closing price
Capitalization
29.17M
67 days until earnings call
Interact to see
Advertisement

EDIT vs IGXT

Header iconEDIT vs IGXT Comparison
Open Charts EDIT vs IGXTBanner chart's image
Editas Medicine
Price$1.92
Change+$0.11 (+6.11%)
Volume$4.11K
Capitalization159.89M
IntelGenx Technologies
Price$0.17
Change-$0.00 (-0.00%)
Volume$37.23K
Capitalization29.17M
EDIT vs IGXT Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. IGXT commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Buy and IGXT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (EDIT: $1.80 vs. IGXT: $0.17)
Brand notoriety: EDIT and IGXT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 164% vs. IGXT: 100%
Market capitalization -- EDIT: $159.89M vs. IGXT: $29.17M
EDIT [@Biotechnology] is valued at $159.89M. IGXT’s [@Biotechnology] market capitalization is $29.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileIGXT’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • IGXT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than IGXT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 6 TA indicator(s) are bullish.

  • EDIT’s TA Score: 6 bullish, 4 bearish.

Price Growth

EDIT (@Biotechnology) experienced а -1.64% price change this week, while IGXT (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 30, 2025.

IGXT is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EDIT($160M) has a higher market cap than IGXT($29.2M). EDIT YTD gains are higher at: 41.732 vs. IGXT (0.000). IGXT has higher annual earnings (EBITDA): -8.16M vs. EDIT (-233.11M). EDIT has more cash in the bank: 270M vs. IGXT (772K). IGXT has less debt than EDIT: IGXT (16.5M) vs EDIT (35M). EDIT has higher revenues than IGXT: EDIT (32.3M) vs IGXT (1.05M).
EDITIGXTEDIT / IGXT
Capitalization160M29.2M548%
EBITDA-233.11M-8.16M2,858%
Gain YTD41.7320.000-
P/E RatioN/AN/A-
Revenue32.3M1.05M3,073%
Total Cash270M772K34,974%
Total Debt35M16.5M212%
FUNDAMENTALS RATINGS
EDIT vs IGXT: Fundamental Ratings
EDIT
IGXT
OUTLOOK RATING
1..100
1647
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
5970
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for IGXT (88) in the null industry. This means that EDIT’s stock grew somewhat faster than IGXT’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IGXT (100) in the null industry. This means that EDIT’s stock grew similarly to IGXT’s over the last 12 months.

EDIT's SMR Rating (95) in the Biotechnology industry is in the same range as IGXT (99) in the null industry. This means that EDIT’s stock grew similarly to IGXT’s over the last 12 months.

EDIT's Price Growth Rating (59) in the Biotechnology industry is in the same range as IGXT (70) in the null industry. This means that EDIT’s stock grew similarly to IGXT’s over the last 12 months.

IGXT's P/E Growth Rating (4) in the null industry is significantly better than the same rating for EDIT (100) in the Biotechnology industry. This means that IGXT’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDIT
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY593.05-2.88
-0.48%
SPDR® S&P 500® ETF
AAPL200.63-2.19
-1.08%
Apple
GME29.45-0.50
-1.67%
GameStop Corp
BTC.X101575.950000-3156.031200
-3.01%
Bitcoin cryptocurrency
TSLA284.70-47.35
-14.26%
Tesla

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-1.10%
CRSP - EDIT
55%
Loosely correlated
+1.37%
AXON - EDIT
52%
Loosely correlated
+1.08%
PRME - EDIT
50%
Loosely correlated
+3.79%
VCYT - EDIT
49%
Loosely correlated
-1.17%
NTLA - EDIT
48%
Loosely correlated
-1.30%
More

IGXT and

Correlation & Price change

A.I.dvisor tells us that IGXT and ACET have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IGXT and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGXT
1D Price
Change %
IGXT100%
N/A
ACET - IGXT
28%
Poorly correlated
-5.25%
DTIL - IGXT
27%
Poorly correlated
+1.27%
EDIT - IGXT
25%
Poorly correlated
-1.10%
CRSP - IGXT
24%
Poorly correlated
+1.37%
BCRX - IGXT
24%
Poorly correlated
-0.63%
More